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Psoriasis is a common, relapsing inflammatory skin disease characterized by erythematous scaly plaques. 
Histological manifestations of psoriasis include keratinocyte dysregulation and hyperproliferation, elongated 
rete ridges, and inflammatory infiltrates consisting of T cells, macrophages, dendritic cells, and neutrophils. 
Despite the availability of new effective drugs to treat psoriasis, the underlying mechanisms of pathogenesis 
are still poorly understood. Recent studies have shown that Aldara cream, used to treat benign skin abnormali-
ties, triggers psoriasis-like disease in humans and mice and have implicated Th17 cells in disease initiation. 
Using this as a model, we found a predominant role for the Th17 signature cytokines IL-17A, IL-17F, and IL-22 
in psoriasiform plaque formation in mice. Using gene-targeted mice, we observed that loss of Il17a, Il17f, or 
Il22 strongly reduced disease the severity of psoriasis. However, we found that Th17 cells were not the primary 
source of these pathogenic cytokines. Rather, IL-17A, IL-17F, and IL-22 were produced by a skin-invading 
population of γδ T cells and RORγt+ innate lymphocytes. Furthermore, our findings establish that RORγt+ 
innate lymphocytes and γδ T cells are necessary and sufficient for psoriatic plaque formation in an experimen-
tal disease model that closely resembles human psoriatic plaque formation.
Introduction
Psoriasis is a complex, multifactorial disease, manifesting in an 
inflammatory response in the skin. The exact mechanistic under-
pinnings of psoriatic plaque formation are yet to be defined (1). 
It has been reported that psoriasis occurrences and relapses were 
inadvertently induced in patients that received topical treatment 
with Aldara, a cream containing imiquimod (IMQ) (2). In mice, the 
application of Aldara induces pathology that largely resembles the 
human disease phenotype of psoriasis (3). Moreover, it was shown 
to be similarly dependent on IL-23, and IL-17RA signaling, sug-
gesting a role of Th17 effector cells (3–5). Recent studies have sug-
gested a role for IL-17–producing γδ T cells in human psoriasis 
(6, 7). Here we report that initiation of plaque formation in the 
Aldara psoriasis model is dependent on RORγt+, skin-infiltrating 
γδ T cells, and innate lymphoid cells (ILCs). Our observations favor 
the notion that rather than Th cells, Vγ4+ γδ T cells and ILCs are 
the dominant and critical source of IL-17A, IL-17F, and IL-22 in 
the formation of acute psoriasiform lesions.
Results and Discussion
IL-17A, IL-17F, and IL-22 are critical for psoriatic plaque formation. 
After daily topical application of Aldara, we observed significant 
thickening, reddening, and scaling of the skin after 3 days (Supple-
mental Figure 1A; supplemental material available online with this 
article; doi:10.1172/JCI61862DS1). The clinical course of plaque 
formation and histopathology for the ear and the back skin were 
similar, with a slightly different kinetics (Supplemental Figure 1B). 
Aldara treatment resulted in hyperproliferation of keratinocytes 
and disturbed epidermal differentiation, as indicated by acantho-
sis and hyperparakeratosis. An additional feature, reminiscent of 
Munro’s microabscesses in human psoriasis, was the accumula-
tion of terminal neutrophils (myeloperoxidase [MPO] staining) in 
the stratum corneum. Additionally, in the dermis extensive infil-
tration of leukocytes was observed (Supplemental Figure 1C).
Responsiveness to conventional antipsoriatic therapies is a hall-
mark for a valid psoriasis model (8). Ustekinumab (IL-12/23p40 
monoclonal antibody) is one of the most efficacious treatments 
for psoriasis (4). Mice that were injected with a single dose of neu-
tralizing murine IL-12/23p40 antibody displayed significantly less 
skin inflammation compared with control mice (Figure 1, A and B). 
Together with the recent finding that Aldara-induced psoriasi-
form plaques are responsive to UVB therapy (9), this disease model 
very closely resembles human disease visually and histologically 
and responds to known antipsoriatic therapies (1).
Skin-invading lymphocytes were analyzed for cytokine pro-
duction at peak disease. IL-17F+ lymphocytes were substantially 
more abundant than IL-17A– and IL-22–producing cells in the 
skin of Aldara-treated mice (Figure 1C). We tested individual 
contributions of the implicated cytokines using Il17a–/–, Il17f–/–, 
and Il22–/– mice and found a significant reduction in the per-
centage change in skin thickness in all of the mutant mouse 
strains, compared with wild-type mice (Figure 1D). Histological 
analysis of the inflammation revealed a significant decrease in 
acanthosis in Il17a–/–, Il17f–/–, Il22–/– mice compared with wild-
type mice, with the most pronounced effects in mice lacking 
IL-17F and IL-22 (Figure 1E). The fact that there were more 
skin-invading cells secreting IL-17F than IL-17A is in line with 
the stronger disease resistance in Il17f–/– compared with Il17a–/– 
mice. IL-17AF heterodimers have been described as sharing the 
biological properties with IL-17A and IL-17F (10), and we found 
significantly increased levels of IL-17AF heterodimers in the 
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draining LNs, as well as slightly elevated levels in the inflamed 
skin of wild-type mice (Figure 1F).
An IL-17A–, IL-17F–, and IL-22–dependent mechanism of 
inflammation is in line with the TLR7 agonistic activity of IMQ 
(11), as skin inflammation could not be induced in Tlr7–/– mice. 
The induction of keratinocyte hyperproliferation in Tlr7–/– mice, 
however, revealed TLR7-independent activities of Aldara (Supple-
mental Figure 1D). Apart from additional active ingredients in the 
Aldara cream formulation (M. van den Broek, unpublished obser-
vations), TLR7-independent pathways of keratinocyte activation 
have been previously reported by others (12).
RORγt+ γδ T cells and innate lymphocytes are the main producers of 
IL-17A, IL-17F, and IL-22 in psoriasiform plaques. The transcription 
factor Rorγt is required for IL-17 and IL-22 production (13, 14). 
To determine the main producers of these cytokines, we used Rorc-
Cre × EYFP fate-mapping mice. Surprisingly, only a small propor-
tion of the cytokine producers were CD4+ Th cells. In contrast, 
about 80% of IL-17A as well as nearly 60% of IL-22 were produced 
by γδ T cells. The remaining IL-17A and IL-22 producers were 
RORγt+CD3– ILCs, accounting for 10% of IL-17A and approxi-
mately 40% of IL-22 (Figure 2, A and B).
There is one report suggesting that human γδ T cells can poten-
tially upregulate TLR7 expression and thus are equipped to respond 
to IMQ (15), but we failed to observe a direct effect of Aldara or 
IMQ in purified murine Vγ4 T cells (data not shown). There is, how-
ever, emerging evidence that conventional DCs initiate the immune 
response to IMQ (B. Clausen, unpublished observations).
At steady state, γδ T cells in the murine skin are primarily repre-
sented by Vγ5+ resident epidermal cells (nomenclature according 
to ref. 16), termed dendritic epidermal T cells (DETCs), a cell pop-
ulation not found in human skin. Recently, it was shown that the 
dermis also contains Vγ4+ resident cells expressing Rorγt, CCR6, 
and IL-17A (17, 18). Staining for the γδ lineage (γ chain) of the lym-
phocytes responsible for the observed Aldara skin inflammation 
revealed that there were two distinct populations (Supplemental 
Figure 2A). DETCs represented the TCRγδhi cells, and the major-
Figure 1
IL-17A, IL-17F, and IL-22 are important for psoriatic plaque formation. (A and B) WT mice were treated with Aldara and anti–IL-12/23p40 mAb 
or isotype control on day 2. (A) Kinetics of skin inflammation as percent increase in thickness over 6 days (n = 4). (B) Skin sections were stained 
with H&E and anti-MPO. Scale bars: 100 μm. (C) Dot plots display the secretion of IL-17A, IL-17F, and IL-22 among CD45+ cells from the skin of 
wild-type mice on day 5 of Aldara treatment. (D and E) WT, Il17a–/–, Il17f–/–, and Il22–/– mice were treated with Aldara or control cream for 5 days. 
Scatter plot shows percent increase in skin thickness (n = 4) (D). Skin sections of Aldara-treated mice taken on day 6 (E) were stained with H&E. 
Scale bar: 100 μm. (F) IL-17AF heterodimer concentration was measured in the supernatant of LN or skin cells cultured for 24 hours using IL-17AF 
FlowCytomix Simplex kit (eBioscience). Each experiment was performed independently at least 3 times. *P < 0.05, **P < 0.01, #P < 0.001.
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ity of TCRγδmed cells were Vγ4+ (Supplemental Figure 2B). Upon 
disease induction, only the frequency (Supplemental Figure 2C) 
and total number of dermal Vγ4+ cells increased, whereas DETC 
numbers were unaltered (Supplemental Figure 2D). Intracellular 
cytokine staining of γδ subpopulations in the skin at peak dis-
ease revealed that Vγ4+ cells produced IL-17F and IL-22, whereas 
DETCs did not (Figure 2C), suggesting that Vγ4+ cells drive the 
inflammatory skin alteration in this model.
To verify this, we compared the responses to Aldara in Tcrb–/–, 
Tcrd–/–, and wild-type mice. Tcrb–/– mice developed inflammation 
similar to that in wild-type mice. In contrast, Tcrd–/– mice had dras-
tically lower, but still noticeable inflammation in the skin (Fig-
ure 2D). It is also possible that the γδ T cell pool in Tcrb–/– mice is 
altered due to the developmental changes in the γδ lineage in the 
thymus (19). However, Cai and colleagues, using Tcra–/– mice, also 
found them to be fully susceptible to IL-23–induced plaque forma-
tion (6). Therefore these findings show that γδ T cells are 
indeed necessary for psoriasiform plaque formation.
Tcrd–/– mice lack both Vγ4+ cells and DETCs. To for-
mally rule out the involvement of DETCs in plaque 
formation, we treated wild-type and Il15ra–/– mice, in 
which DETCs do not develop (Supplemental Figure 
2E), with Aldara and found inflammation to be indis-
tinguishable (Figure 2E).
We found a similar increase in proliferation of Vγ4+ cells 
in both the skin and skin-draining lymph nodes, suggest-
ing that cytokine-secreting Vγ4+ cells are not predomi-
nantly skin resident (Supplemental Figure 2F). A recent 
study on psoriasis in humans has demonstrated that a 
subset of γδ T cells seems to play a role in disease develop-
ment and that these cells express high levels of CCR6 and 
cutaneous leukocyte antigen (CLA) (7). Correspondingly, 
we found Vγ4+ cells to express the relevant skin-homing 
receptors CLA and CCR6, which could facilitate their 
recruitment to the skin (Supplemental Figure 2G).
RORγt+ innate lymphocytes are essential for psoriasiform 
plaque formation. Direct comparison of Tcrd–/– and Rag1–/– 
mice revealed that both were relatively protected from 
Aldara-induced skin inflammation, with Tcrd–/– mice 
seemingly slightly more protected (Figure 3A). Cyto-
fluorimetric comparison of the skin infiltrates revealed 
an increase in the number of ILCs in Rag1–/– compared 
with Tcrd–/– and wild-type mice. ILCs in Rag1–/– mice had 
higher levels of CLA expression, but no major difference 
was found in regard to the expression of NKp46 or CD4 
(Supplemental Figure 3, A–E).
Analysis of Aldara-treated skin revealed a small population of 
Lin–NKp46– cells that were significant (P = 0.0076) producers 
of IL-22 (Figure 3B). Fate-mapping of ILCs in Rorc-cre × YFP × 
Rag1–/– mice showed that they invade the cellular niche of T cells 
and drive some degree of inflammation through increased pro-
duction of IL-22 (Figure 3C). Using these mice, we also found 
ILCs to drastically increase IL-22 production in response to IL-23 
(Supplemental Figure 3F). To confirm the role of ILCs in psoria-
siform plaque formation, we analyzed the severity of inflamma-
tion by comparing Rag1−/− mice, which lack T and NKT cells, with 
Rag2–/–Il2rg–/–, which additionally lack NK cells and ILCs. In con-
trast to Rag1–/– mice, Rag2–/–Il2rg−/− mice were completely resistant 
to Aldara-driven plaque formation (Figure 3D).
Thus far, our findings show the reliance of Aldara-induced psori-
asis-like phenotype on ILCs and γδ T cells, which are largely depen-
dent on the transcription factor RORγt for their cytokine pro-
Figure 2
RORγt+ γδ T cells and innate lymphocytes are the main 
producers of IL-17A, IL-17F, and IL-22 in psoriasiform 
plaques. (A) Intracellular cytokine staining in the skin of 
Rorc-Cre × EYFP mice after 5 days of Aldara treatment, 
gated on CD45+ cells (n = 3), with (B) scatter plots showing 
percent distribution (n = 3). (C) Cytokine staining of V4γ+ 
versus Vγ5+ for IL-17F and IL-22, pre-gated on TCRγδ+ 
cells. (D and E) Kinetics of Aldara-induced skin inflamma-
tion in (D) WT versus Tcrb–/– and Tcrd–/– mice (n = 4) and 
(E) WT versus Il15ra–/– mice (n = 3), shown as the percent 
increase in skin thickness. Each experiment was performed 
independently at least 3 times.*P < 0.05, #P < 0.001.
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duction (13, 14). Consequently, as in Rag2–/–Il2rg−/− mice, no skin 
inflammation or thickening was observed in Rorc–/– mice (Figure 
3E). Moreover, IL-17A, IL-17F, and IL-22 were virtually absent in 
the skin of these mice compared with wild-type mice (Figure 3F and 
data not shown). Therefore, Aldara-induced psoriasiform plaque 
formation seems to be completely dependent on the transcription 
factor RORγt in Vγ4+ γδ T cells and RAG-independent ILCs.
We set out to dissect the cellular underpinnings of psoriatic 
plaque formation and employed a recently described mouse model 
(3). Aldara-induced inflammatory lesions bear a substantial num-
ber of major hallmark histopathological and molecular features of 
human psoriatic plaques (1). The model is, however, limited to the 
simulation of psoriatic plaque formation, whereas the underlying 
natural pathogenic trigger of psoriasis, or any aspect of chronifica-
tion of the inflammation, cannot be addressed. In a study paral-
lel to ours, Cai and colleagues reported the pivotal role of dermal 
γδ T cells and their production of IL-17A in IL-23–induced skin 
inflammation in mice (6) and found evidence for their involve-
ment in human psoriasis (6, 7). Some supporting evidence has also 
been reported in studies using the Aldara-induced psoriasis model 
(6, 20), which our study links to with an in-depth analysis of the 
pathophysiologic events during psoriatic plaque formation.
In summary, our data show that Rorγt-dependent ILCs and γδ 
T cells are necessary and sufficient to drive psoriasiform plaque 
formation in mice through the collective delivery of IL-17A, 
IL-17F, and IL-22 to the skin. The current notion that IL-23 
induces Th17 cells stems from the observation that activated 
 T cells are a major part of the skin-infiltrating immune cells and 
are a known source of these cytokines. Only recently have innate 
lymphocytes been acknowledged to be highly effective producers 
of these mediators. The fact that OKT3 antibody depleted human 
T cells was interpreted to indicate that psoriasis is dependent 
on CD4+ and CD8+ T cells (21), even though it also depletes γδ 
T cells (22). Without dismissing adaptive immune processes in the 
etiology of psoriasis, our study does establish the sufficiency of a 
dysregulated innate immune compartment for psoriatic plaque 
formation. Thus, our proposed paradigm of lesion development 
not only provides a new basis for understanding the therapeutic 
efficacy of new biological drugs to treat human psoriasis, but may 
also lead to more in depth research on γδ T cell and ILC involve-
ment in human disease.
Methods
Further information is available in Supplemental Methods.
Mice. C57BL/6 (wild-type) mice were obtained from Janvier. RorcGFP/GFP 
(in text referred to as Rorc–/–), Tcrβδ–/–, Rag1–/–, and Rag2–/–Il2rg−/− mice were 
purchased from The Jackson Laboratory. Tcrb–/– and Tcrd–/– mice were bred 
from Tcrβδ–/– mice. Rorc-Cre crossed with Rosa26-stop-eYFP mice (called 
Figure 3
RORγt+ innate lymphocytes are essential for psoriasiform plaque formation. (A) Kinetics of Aldara-induced skin inflammation in WT versus 
Tcrd–/– versus Rag1–/– mice. (B) Cytokine staining in ILCs in the skin of Aldara- versus control-treated mice, pre-gated on Lin–CD45+ cells (n = 3). 
(C) Fate map analysis and IL-22 staining in the Aldara-treated skin of Rorc-Cre X EYFP and Rorc-Cre × EYFP × Rag1–/– mice gated on CD45+ 
cells. Kinetics of Aldara-induced skin inflammation in (D) WT versus Rag1–/– versus Rag2–/–Il2rg−/− mice and (E) WT versus Rorc–/– mice showing 
percent change in skin thickness (n = 3). (F) Staining for IL-17F and IL-22 in CD45+ cells from the skin of control and Aldara-treated WT versus 
Rorc–/– mice (n = 3). Each experiment was performed independently at least 3 times. #P < 0.001.
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Rorc-Cre × EYFP mice herein) were provided by A. Diefenbach (University 
of Freiburg, Freiburg, Germany), Il17a−/− mice by Y. Iwakura (University of 
Tokyo, Tokyo, Japan), Il17f–/– mice by Merck Serono S.A., Il22−/− mice by J.C. 
Renauld (Université Catholique de Louvain, Yvoir, Belgium), and Il15ra−/− 
mice by S. Bulfone-Paus (University of Giessen, Giessen, Germany).
Treatment. The mouse back was shaved, and a daily dose of 50 mg of 
Aldara (5% IMQ cream; 3M Pharmaceuticals) or control vehicle cream (Soft 
Kreme KA, Kantonsapotheke Zürich) was applied on the back and 5 mg 
to each ear for 5–7 days. Anti–IL-12/23p40 treatment was performed by 
injection of the mice with 200 μg/mouse rat anti–mouse IL-12/23p40 mAb 
(C17.8) and respective IgG2A isotype control antibody (2A3, both Bio X 
Cell) on day 2 of Aldara application.
Cell preparation. Skin and ears were cut into small pieces and digested 
with 1 mg/ml collagenase type IA and 100 mg/ml DNase (Sigma-Aldrich) 
for 60 minutes at 37°C. Isolation of leukocytes from the LN involved teas-
ing the organs apart. Both were followed by filtering through 70-μm cell 
strainers to obtain single-cell suspensions.
Antibodies. Cells were incubated with antibodies for 20 minutes at 4°C. 
For intracellular cytokine staining, cells were stimulated with PMA (Appli-
chem) and ionomycin (Invitrogen) and treated with GolgiStop (BD) for 
3 hours. After surface staining, cells were permeabilized according to the 
manufacturer’s (BD) recommendations and stained intracellularly. Stain-
ings were analyzed with a FACS LSRII Fortessa (BD). Post-acquisition 
analysis was performed with FlowJo (Tree Star) software.
Histology. Tissue samples were fixed in 4% paraformaldehyde and embed-
ded in paraffin. Deparaffinized sections were stained using H&E. Immu-
nohistological staining for MPO (1:100, rabbit, Thermo Scientific) was per-
formed by a Ventana Benchmark XT automated staining system according 
to the manufacturer’s guidelines.
Statistics. For disease severity, differences between groups were evaluated 
by 2-way ANOVA with Bonferroni’s post hoc test. For analysis of scatter 
plots of maximum thickness comparing ≥3 groups of mice, 1-way ANOVA 
with Bonferroni’s post-test was used. Differences between two sets of data 
were evaluated by 2-tailed Student’s t test. Data represent mean ± SEM. 
 P ≤ 0.05 was considered statistically significant. All statistics were done 
using GraphPad Prism (GraphPad Software).
Study approval. All animal experiments were approved by the Swiss Can-
tonal Veterinary Office (33/2010; Zurich, Switzerland).
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